LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
DiaSorin, Inc. · Decision date Oct 10, 2025
What did the FDA approve?
FDA records P220034/S007 as a supplement to PMA P220034, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 10, 2025.
FDA approval order statement
Approval for the use of an alternative polypropylene resin for production of the plastic vials hosting the LIAISON assays reagents
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Microbiology
- Decision date
- Oct 10, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P220034/S007
- Regulatory pathway
- PMA supplement
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- Decision code
- APPR
- Decision date
- Oct 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.
- Applicant
- DiaSorin, Inc.
- Product code
- MYL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220034/S007 received
Application receipt date recorded by FDA.
P220034/S007 · FDA decision
Real-Time Process
P220034/S008 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S011 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
P220034/S010 · Related supplement
LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus
Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jun 24, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P220034/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
